Definitive Contract HHSN261201200087C

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...

This is a $20,300 firm fixed price contract awarded by the National Cancer Institute (NCI) to Nanostring Technologies, Inc. to provide the NCI with specialized laboratory equipment, reagents, assays, and testing services to support genomic, molecular, and cellular analysis for biomedical research and healthcare programs. The contract is a blanket purchase agreement (BPA) call order that allows the NCI to procure products and services compatible with Nanostring's nCounter Analysis Systems and...

This is a $199,987.00 firm fixed price definitive contract awarded by the National Cancer Institute, a civilian agency, to Genome Data Systems Inc., a minority-owned, small disadvantaged business, for &quot;OTHER FUNCTIONS GENOME &quot;PHASE I, TOPIC 309, LABEL FREE MULTIVARIATE CANCER DIAGNOSIS&quot;&quot;. The contract has a total small business set-aside designation and was awarded on September 28, 2012, with a completion date of June 27, 2013. Genome Data Systems Inc. has previously received...

This is a $9,900 firm fixed price BPA call awarded by the National Cancer Institute (NCI) to Nanostring Technologies, Inc. The contract is for the provision of Nanostring's proprietary NanoString nCounter Analysis Systems and GeoMx Digital Spatial Profilers, along with associated reagents and consumables, to support genomic, molecular, and cellular analysis for biomedical research and healthcare programs across various government agencies. Nanostring Technologies is a publicly held provider of...

<p>This is a $199,386 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Sensopath Technologies, Inc., a woman-owned small business. The contract is for &quot;TAS::75 0849::TAS TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS&quot; and has a period of performance through July 8, 2011. The contract was set aside for small businesses.</p>

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This is a $199,892.00 federal contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a for-profit small business. The contract is for basic research and development in the &quot;OTHER FUNCTIONS R &amp; D- BIOMEDICAL (BASIC RESEARCH)&quot; domain as part of the SBIR Program Phase I. The contract is a definitive, firm fixed-price agreement with a completion date of June 21, 2013. This contract award has a total small business set-aside designation.

This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of &quot;MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY&quot;, which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...

<p>This is a $191,326 firm-fixed-price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lipomedics LTD, a small business limited liability company, to reformulate cancer therapeutics using nanotechnology. The contract has a ceiling value of $191,326 and an ultimate completion date of November 1, 2013. This contract is set aside for total small business participation.</p>